APYX
Apyx Medical Corporation
APYX lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
APYX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Unavailable |
APYX's revenue is currently healthy, and its profitability is stable, but its cash flow is under pressure. There isn't enough data to rate its balance sheet.
APYX PE Valuation
APYX has no meaningful PE right now: it lost money over the past year.
APYX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect APYX's losses to shrink, with revenue growing.
APYX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.19 | +$0.18 |
| Q2 2026 | -$0.20 | +$0.26 |
| Q1 2026 | -$0.22 | +$0.34 |
| Q4 2025 | -$0.27 | +$0.41 |
| Q3 2025 | -$0.37 | +$0.46 |
| Q2 2025 | -$0.46 | +$0.36 |
| Q1 2025 | -$0.56 | +$0.10 |
| Q4 2024 | -$0.68 | -$0.14 |
APYX is still losing money, but far less than before: $0.19 per share over the past year, against $0.83 at its worst in late 2024.
APYX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $14M | +9% |
| Q2 2026 | $13.9M | +22% |
| Q1 2026 | $12.5M | +32% |
| Q4 2025 | $19.2M | +35% |
| Q3 2025 | $12.9M | +12% |
| Q2 2025 | $11.4M | -6.4% |
| Q1 2025 | $9.4M | -7.9% |
| Q4 2024 | $14.2M | -3% |
APYX's revenue has grown year over year for five quarters in a row: $14M last quarter, up 9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -4.1% | +2.4 points |
| Q2 2026 | -13% | +9.6 points |
| Q1 2026 | -7.3% | +25 points |
| Q4 2025 | 0.1% | +22 points |
| Q3 2025 | -6.5% | +25 points |
| Q2 2025 | -23% | +23 points |
| Q1 2025 | -32% | +32 points |
| Q4 2024 | -21% | +18 points |
APYX's operating margin was −4.1% last quarter, up 2.4 points from the same quarter a year ago, near the top of its range since 2019.
APYX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.9M | +$2.2M |
| Q2 2026 | -$3.6M | -$2.1M |
| Q1 2026 | -$632K | +$125K |
| Q4 2025 | -$2.8M | +$377K |
| Q3 2025 | -$4.1M | +$538K |
| Q2 2025 | -$1.5M | +$3.1M |
| Q1 2025 | -$757K | +$5.6M |
| Q4 2024 | -$3.2M | -$877K |
APYX has burned cash in almost every quarter: −$9M over the past year, against −$9M the year before.
APYX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +195K shares |
| 1 year | +8.1% | +3.3M shares |
| 3 years | +27% | +9.4M shares |
| 5 years | +28% | +9.7M shares |
| Available history | +29% | +10M shares |
APYX has 44M diluted shares, up 8.1% from a year ago.
APYX Net Leverage
APYX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
APYX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.3 | Neutral |
| Stochastic | 28.7 | Neutral |
APYX's weekly RSI is 44 (neutral) and its Stochastic is 29 (neutral).
APYX PE vs Healthcare Sector
APYX has no meaningful PE right now: it lost money over the past year.
APYX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.68 | 7.8% above |
| 20 week MA | $3.24 | 11% below |
| 50 week MA | $3.58 | 19% below |
| 100 week MA | $2.77 | 4.3% above |
| 200 week MA | $2.73 | 5.9% above |
APYX's trend is mixed: it's above three of its five weekly moving averages, and 5.9% above its 200-week average.
APYX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.23 | $7.04 | -14% |
| 2021 | $7.04 | $13.1 | +86% |
| 2022 | $13.1 | $1.99 | -85% |
| 2023 | $1.99 | $2.62 | +32% |
| 2024 | $2.62 | $1.64 | -37% |
| 2025 | $1.64 | $3.44 | +110% |
| 2026 YTD | $3.44 | $2.89 | -16% |
APYX's yearly returns have swung widely, from +110% in 2025 to −85% in 2022. It's down 16% so far in 2026.